Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Clinical Pharmacology, Therapeutics & Intro to Prescribing > Lecture 3- Pharmacokinetics and pharmacodynamics > Flashcards

Lecture 3- Pharmacokinetics and pharmacodynamics Flashcards

1
Q

some things to consider when thinking about pharmakinetics (patient factors)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

after a drug has entered systemic circulation (absorbed)

A
  1. it can stay free
  2. it can bind and unbind to its target receptor
  3. it can enter tissue reservoirs (where is can bind to proteins or adipose)
  4. it can bind to protein in the blood (albumin)
  5. it can be metabolised (to become active or inactive)
  6. it can be excreted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical consideration of PK influences MHRA (medicines and healthcare products regulatory agency) and FDA approval and standard dosing. Key factors

A
  • Bioavailability
  • Half-life
  • Drug elimination
  • Inter-subject variability
  • Drug-drug interactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Absorption

A

Used to describe the journey of a drug travelling from the site of administration to site of action. ​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bioavailability (F)

A
  • Measure of drug absorption where is can be used
  • Drugs administered via intravenous bolus is said to have 100% bioavailability
  • Oral dose will not be 100%
  • Therefore : other routes references a fraction of IV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

bioavailability is affected by

A

absorption and first pass metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

absorption and bioavailability

A
  • Formulation i.e. oral or IV
  • Age
  • Food (chelation, gastric emptying)
  • Vomiting/malabsorption
  • Previous surgery (bariatric)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

First pass metabolism

A
  • Metabolism before reaching systemic circulation
  • E.g. drugs absorbed in GI, goes straight to the liver via the hepatic portal vein and is metabolised before reaching systemic circulation
  • E.g. metabolised in the lungs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Rate of absorption

A
  • Plasma conc-time graphs show distinct phases
  • Rate of absorption dictates the visibility of distribution and elimination phases
  • Look at the initial gradient of [plasma/ time curve]
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

if absorption is very quick

A

(steep gradient)

distinct phase between the absorption and distribution (circled part on graph)

  • Rise in plasma conc very quickly
  • Then distribution as the drug distributes through the tissue (pronounced drop on the graph- coving)
  • Run off phase with elimination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

If absorption is slow

A

then the absorption and distribution phase will be occurring at the same time – no coving on the graph seen- slightly less steep accumulation of drug in the plasma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Manipulating absorption of drugs using modified release preparation

A

we want to keep drug concentration within the therapeutic range as long as possible

  • If elimination is rapid large fluctuations in [plasma] will be seen
    • Large periods of time below minimum effective concentration
    • Periods of time above the maximum safe conc- side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how do modified preparations work

A
  • Plasma conc becomes more dependent on the rate of absorption vs rate of elimination
  • Can help with adherence
    • E.g. if fast onset release medication is causing bad side effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Some factors affecting therapeutic agent distribution- Volume of distribution (Vd)= function of these factors

A
  • Blood flow
    • Better distribution in highly vascularised tissue
  • Capillary structure
  • Lipophilicity
    • Drugs can pass through plasma membrane
  • Hydrophilicity
    • Drugs pass through aqueous channels
  • Protein binding (sequesters drug, changing PK in terms of distribution)
    • Albumin- acidic drugs (most common)
    • Globulins- hormones
    • Lipoproteins- basic drugs
    • Glycoproteins- basic drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

distribution and multiple compartments

A

Rate of distribution and equilibration from IV admin typically follows a multiple compartment model

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Drug protein binding and distribution

  • *
A
  • Typically only free drugs will afford response at target receptor site and/ or be eliminated
  • Displacement of a drug from binding site can result in protein binding drug interaction
  • If highly protein bound
    • Narrow therapeutic index
    • Low Vd
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Increased free drug will be able to afford increased response or be eliminated

A
  • E.g. if a second drug is given that displaces first drug from binding protein
  • More free drug to elicit a response
    • Potentially causing harm e.g. pregnancy (fluid balance), renal failure, hypoalbuminemia (amount of protein in diet will change the amount of albumin in plasma- effect amount of free drug)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

(apparent) Volume of distribution

A
  • It is a proportionality factor
    • Dose/[drug]plasma
  • We can’t easily measure whole body drug concentration- only blood plasma
    • Concentration = the amount of solute in given volume
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

calculate this Vd (1)

A

100mg/ 20 mg/L= 5l (Vd)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

calculate this Vd (2)

A
  • High proportion of adipose in compartment increases amount dissolved, limiting amount dissolved in the plasma
  • Vd = 100/5 ug/mL = 20L
    • 5ug/mL = 5 mg/L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

calculate Vd of (3)

A

always remmeber units

  • High protein binding. Plasma conc slightly higher than in high adipose example. Vd= 100/10= 10L
    • 10 ug/mL= 10mg/L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

calculate presuming dose is 100mg/L

A
  • Lipophilic drug.
  • Plasma conc 500 ng/mL = 0.5 mg/L.
  • Vd= 100/0.5= 200L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what does a Vd of 200L mean

A

200L of fluid would be required to have a drug conc of 0.5mg/L in the plasma–> very high Vd (not much found in the plasma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

a smaller Vd suggest

A

drug is confied to plasma and ECF

–> may need to use a lower conc of the drug since more stays in the plasma where the drug can be active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

a larger apparent Vd suggest

A

drug is distributed throughout tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

2 women are both 5’7 but one weighs 58kg and the other 70kg. Who will have the lower Vd of a drug if

A

58kg women

  • lower body mass, therefore less adipose for drug to distribute into
  • higher conc of drug stays in the plasma
  • may need a lower dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

clinical relavance of Vd

A

can help determine dose to be givenn

Vd= Dose/ [Drug] plasma

therefore

Dose=Vd x [Drug] plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

outline drug metabolism

A

Several sites of activity, liver having the most numerous and diverse metabolic enzymes

Size, lipophilicity, hydrophobicity, structural complexity affects route and mechanism

  • Some drugs only go through phase I
  • Some just go through phase II
  • Some go through phase I or phase I
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

why do drugs need to be metabolised

A
  1. to turn them on i.e. pro drug –> drug
  2. Hydrophobic species need to be made more ionic (molar)- hydrophilic to enable elimination via the kidneys
    • Lipophilic species would be reabsorbed and stay in the systems
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

which enzyme catalyse the majority of phase 1 reactions

A

Cytochrome P450 (CYPs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Cytochrome P450 (CYPs)

A
  • Oxidation reaction most important
  • Found abundantly in smooth ER in hepatocytes
  • Numerous genes that encode these enzymes, CYP families 1-4 deals with most reaction
33
Q

What do CYPs do to drugs

A
34
Q

CYPs can be induced or inhibited by endogenous/exogenous compounds affecting phase I metabolism

A
  • Age increase = reduced activity of CYPs
  • Hepatic disease = reduced activity of CYPs
  • Blood flow = increased flow (decreased effect of CYPs), decreased flow (increased effect of CYPs)
  • Cigarette smoking= increased activity of CYPs
    • If someone stops smoking may need to think about dose of drug
35
Q

Clinical importance of CYPS

A

Important for drug prescribing and complexity of polypharmy

36
Q

example of counter/herbal preparations which can induce/inhibit CYPs

A
  • St Johns Wort (P450)
    • Taken as a mood stabiliser
  • Valerian
  • Grapefruit juice
  • Alcohol
37
Q

other factors which effect activity of CYPs

A
  • Race
  • Sex- women slower ethanol metabolisers
  • Species (need to think about this with drug development)
38
Q

example of self induced metabolism

A
  • E.g. carbamazepine induces CYP3A4 and is also a substrate for CYP3A4
39
Q

CYP inhibition example

A

e.g. Grapefruit juice inhibits CYP3A4, which is an important enzyme in the breakdown and elimination of statins

40
Q

genetic factors and CYPs

A

CYP 2D6 (substrates inc B-blockers, many SSRs and some opioids)

  • Missing in 7% of Caucasians
    • Drug toxicity
    • Cant metabolise drug
  • Hyperactive in 30% east Africans
    • Hard to get to therapeutic level of drugs
    • E.g. wont feel effect of opioids
  • CYP 2D6 also inhibited by SSRIs, other antiarrhythmic agents and other antidepressants
41
Q

drug excretion via

A
  • Fluids
    • Primarily via the kidneys (20% of systemic blood flow)
    • Other routes: sweat, tears, genital secretions, saliva, breast milk
  • Solids- faeces and hair (e.g. drug testing)
  • Gases- volatile compounds
42
Q

renal excretion

A
  • Typically low molecular weight (small) polar metabolites
  • Affected by
    • GFR (clearance) and protein binding (gentamicin)
    • Competition for transporters such as organic anion transporters (OATs) (penicillin)
    • Lipid solubility, pH, flow rate (aspirin)
  • Manipulation of pH e.g. alkalinising can help treat poisoning and gout à drive excretion e.g. salicylates
    • Think weak acids and bases from ESA1
43
Q

Hepatic

A
  • Typically high molecular weight metabolites- conjugated with glucuronic acid
    • Bile important for conjugates- increased mwt-larger compounds
    • Excreted in faeces or reabsorbed
      • Enterohepatic circulation- environment for recycling of drugs
        • Endogenous examples e.g. bilirubin and steroid hormones
    • Antibiotics may change gut flora which allows conjugates to be disruptedà enterohepatic reabsorption
      • E.g. warfarin, morphine- dose may need adjusting
    • Hepatic disease is of importance when prescribing
      • Changes in CYPs or hepatic excretion
44
Q

First order kinetics (Linear elimination kinetics)

A
  • Elimination of a constant percentage (or fraction) of the drug per unit time (if a large functional reserve of enzymes)
    • That is - if there is Large Functional Reserve and Plenty of Phase I/II Enzyme sites
    • Plenty of OAT/OCT Transporters
  • For most drugs, the elimination occurs at a rate directly proportional to the concentration of the drug—i.e., the higher the drug concentration, the higher its elimination rate (e.g., 50% per unit time, as shown in the figure).
    • Rate of metabolism /transport will be proportional to the number of molecules occupying a catalytic/ carrier site per unit time
45
Q

Zero-order kinetics (Nonlinear kinetics)

A
  • Elimination of a constant quantity of the drug per unit time independent of the concentration of the drugs
  • With a few drugs, such as aspirin, ethanol, and phenytoin, the doses are very large.
  • Therefore, the plasma drug concentration is much greater than the Michaelis constant Km, and drug metabolism is constant and independent of the dose

​

46
Q

which order’s half life can you predict

A

only first order

  • Independent of conc- up to saturation point
  • Half-life is particular for different drug and pharmacokinetic process
  • Elimination half-lives can range from minutes to days (and weeks)
47
Q

Clearance (CL)

A
  • Volume of blood cleared per unit time (mL/min)
  • Constant proportion not amount
  • Independent of [plasma] drug

e.g. if 10% of 1000mL are cleared in 1 min- clearance = 100mL/min

48
Q

celarance and higher drug concentration

A

If a drug concentration is high- more drug in the same volume can be cleared- elimination rate is increased.

49
Q

if plasma levels of drug is low

A

elimination is going to be low

50
Q

elimination rate constant (K) equation

A

therefore we can calculate half life if we know volume of distribution and clearance

51
Q

clinical significance of elimination rate constant

A
52
Q

Elimination kinetics and toxicity

A
  • Most drugs exhibit first order kinetics at therapeutic doses (half life is constant)
  • High doses and alcohol, salicylic acid and phenytoin- zero order
  • Important consideration for toxicity and dosing
53
Q

zero order drugs and toxicity

A
  • Dose change can produce unpredictable change in [plasma]
  • T1/2 not calculable
54
Q

clinical importance of drug monitoring

A
  • Zero order kinetics – the unpredictability
  • Long half-life – dosing and accumulation
  • Narrow therapeutic window – the “goldilocks” zone
  • Drug-drug interactions (metabolic/genetic), measure [plasma] for some drugs (phenytoin…)

Looking out for:

  • Reported or expected toxic effects
  • Therapeutic effect – response that is expected/desired?
55
Q

Steady-state concentration (Css)

A

occurs when the amount of a drug being absorbed is the same amount that’s being cleared from the body when the drug is given continuously or repeatedly- time during which the concentration of the drug in the body stays consistent.

‘The input rate is the same as the elimination rate’

56
Q

For most drugs, the time to reach steady state is

A

four to five half-lives if the drug is given at regular intervals—no matter the number of doses, the dose size, or the dosing interval.

A half-life is how long it takes for half of the drug to be eliminated from the body.

57
Q

why do we measure time to get Css in half lifes

A

let’s assume we administer a dose every half-life. If a single dose is given every half-life, half of the first dose will be cleared from the body before the next dose.

58
Q

therapeutic benefit optimal at

A

steady state (Css/Cpss)

59
Q

after termination of the drug how long does it take for neglible drug to remain

A

4-5 hlaf life’s

  • some drug will still remain (however insuffieicent to elict therapeutic response

(think about traces of recreational drugs)

60
Q

[plasma] at steady state

A

can use the clearance equation to calculate Css. Why?

  • clearance = / rate of elimination from body/ drug concentration in plasma

therefore

….

  • rate of elimination = CL x [plasma]
  • at Css infusion= elimination
  • rate of infusion = CL x Css
    therefore. ..

Css= rate of infusion/Cl

61
Q

dosing can be

A

single (headache) vs multipe (hypertension

62
Q

rate of administration =

A

D= dose

F= bioavailability

t= time

63
Q

rate of elimination=

A

CL x Css

64
Q

at steady state administration =

A

elimination

65
Q

because at steady state adminstation = elimination we can combine the equations to work out Css

A
66
Q

loading dose

A
  • when rapid onset required or a drug with a long half-life
  • is a higher dose administered on treatment initiation.
  • will still take the usual four to five half-lives to reach steady state, but the initial concentration will be closer to the eventual steady-state concentration—which means the therapeutic effect will happen faster.
67
Q

examples of drugs with a loading dose

A
  • E.g. Digoxin, phenytoin, amiodarone (antiarrhythmic drugs)
68
Q

loading dose equation

A
69
Q

Clinical example of loading dose use- Amiodarone

A
  • Large apparent Volume of distribution – very large ~ 66L/kg
    • Lipophilic so gets into lots of compartments
  • Predominantly hepatic metabolism and biliary excretion
  • Long half life – very long 50 – 60 days
  • Css (steady state plasma conc) will be reached in………..
  • If amiodarone is to be used for SVT (not typically first line) then a loading dose is going to be required
    • Give large bolus to start to getting in therapeutic range quickly
70
Q

Amiodarone elimination

A
  • Long t1/2 will result in long period before drug is fully (almost) eliminated from the body - months
  • Important consideration if terminating medication
    • i.e. may increase [plasma] of other cardiac drugs
  • Good example of potential medication error – repeat prescriptions, discharge dose vs. long term dosing
71
Q

Aims of dosing schedules

A
  • Maintain a dose within the therapeutic range
  • Safe
  • Achieve adherence
  • Initiating and terminating treatment- titrating up and down (increase and decreasing dose)
72
Q

therapeutic index/ratio

A

=median toxic/median therapeutics

  • most therapeutic level
73
Q

how do you known you have prescribed successfully

A

Response to drug therapy- knowing you have prescribed successfully!

  • Physiological measurements – BP, WBC, cholesterol…
  • Feeling – MSK, mood, energy
  • Appearance – a rash, infection, wound, scan
  • Primary and secondary prevention – this can be a particular challenge
74
Q

define selectivity

A
  • drugs often act at or can elciit a response at mor ethan one receptor subtype (alpha, beta, LTCC etc)
  • the size of the response always differs between receptor subtypce
  • selectivity can be quantified as the ratio of [drug] that achieves a given level of response at one receptor subtrype vs [drug] needed at the other receptor type
75
Q

problems with selectivity

A

Would ideally like to give Salmeterol- binds really well to B2 and not well to B1 (less side effects). However it is insoluble.

76
Q

affinity

A

stregnth of itneraction between drug and its receptor, governs the recpetor binding dissocaition rate

higher affinity means lower [drug] needed to occupy given proportion of receptors and elicit a given response

77
Q

effciacy

A

ability to produce the maximal response of a particualr system (vasodilation, block calcium channel etc).

efficacy clinically more important than potency- a potent drug may never achieve the response required

78
Q

potency

A

in part determined by affinity and what drug-receptor complex is able to do through its signalling.

in real terms- humans are not expiremnts, [drug] to elicit a given response is influenced by receptor number and PK (EC50 or ED50)

79
Q

example of drug action- PD

A

Clinical Pharmacology, Therapeutics & Intro to Prescribing (39 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions